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Ultrasound to identify systemic lupus erythematosus
patients with musculoskeletal symptoms who
respond best to therapy: the US Evaluation For
mUsculoskeletal Lupus longitudinal multicentre study
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Katherine Dutton1,4, Lee Suan Teh5, Chee-Seng Yee6, David D’Cruz7,
Nora Ng7, David Isenberg 8, Coziana Ciurtin 9, Philip G. Conaghan1,2,
Paul Emery 1,2, Christopher J. Edwards4, Elizabeth M. A. Hensor 1,2 and
Edward M. Vital 1,2
Abstract
Objectives. To determine whether SLE patients with inflammatory joint symptoms and US synovitis/tenosyovitis
achieve better clinical responses to glucocorticoids compared with patients with normal scans. Secondary objec-
tives included identification of clinical features predicting US synovitis/tenosynovitis.
Methods. In a longitudinal multicentre study, SLE patients with physician-diagnosed inflammatory joint pain
received intramuscular methylprednisolone 120 mg once. Clinical assessments, patient-reported outcomes and bilat-
eral hand/wrist USs were collected at 0, 2 and 6 weeks. The primary outcome (determined via internal pilot) was
the early morning stiffness visual analogue scale (EMS-VAS) at 2 weeks, adjusted for baseline, comparing patients
with positive (greyscale 2 and/or power Doppler 1) and negative US. Post hoc analyses excluded FM.
Results. Of 133 patients, 78 had a positive US. Only 53 (68%) of these had one or more swollen joint. Of 66 patients
with one or more swollen joint, 20% had a negative US. A positive US was associated with joint swelling, symmetrical
small joint distribution and serology. The primary endpoint was not met: in the full analysis set (N¼ 133) there was no
difference in baseline-adjusted EMS-VAS at week 2 [7.7 mm (95% CI 19.0, 3.5); P¼0.178]. After excluding 32
patients with FM, response was significantly better in patients with a positive US at baseline [baseline-adjusted EMS-
VAS at 2 weeks 12.1 mm (95% CI 22.2, 0.1); P¼0.049]. This difference was greater when adjusted for treatment
[12.8 mm (95% CI 22, 3); P¼ 0.007]. BILAG and SLEDAI responses were higher in US-positive patients.
Conclusion. In SLE patients without FM, those with a positive US had a better clinical response to therapy.
Imaging-detected synovitis/tenosynovitis may be considered to decide on therapy and enrich clinical trials.
Key words: systemic lupus erythematosus, ultrasound, outcome measures, clinical trials and methods,
biomarkers
Rheumatology key messages
. There is substantial disagreement between clinical examination and ultrasound in SLE patients with inflammatory joint
pain.
. Ultrasound-confirmed synovitis is more likely with symmetrical small joint distribution, higher IgG levels and RNP
antibodies.
. Patients with ultrasound synovitis are more likely to respond to glucocorticoid therapy, provided fibromyalgia is excluded.
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Inflammatory joint disease affects >90% of patients with
SLE and is a major determinant of long-term quality of
life and disability [1, 2]. Our previous work suggests that
this disproportionate impact on quality of life and dis-
ability may be due to undertreatment [1, 3]. SLE patients
often have less joint swelling than RA or PsA patients.
In the BILAG-2004 index [4], A and B scores for the
musculoskeletal domain (indicating active disease need-
ing additional immunosuppression) can only be achieved
if joints are swollen. The SELENA and SLEDAI-2K score
‘arthritis’ if there are at least three or two inflamed joints,
respectively [5, 6]. There is scope for interpretation of
which signs qualify for this ‘inflamed’ criterion, but swel-
ling is often sought before scoring this feature in clinical
trials and routine practice. Patients who fail to score on
these scales invariably fail to qualify for treatment with
biologic therapies [7].
Previous US studies have shown that clinical joint
swelling underestimates synovitis severity, although a
systematic review found several methodological fac-
tors leading to uncertain estimates of the rates of US
synovitis [8]. We therefore conducted a large cross-
sectional study to address these problems and esti-
mated the rates of clinical and US abnormality in SLE
patients presenting with inflammatory joint pain: 38%
had clinical joint swelling and 35% had neither swel-
ling on clinical examination nor evidence of US syno-
vitis. However, 27% of patients had synovitis only
detectable with US. US-only synovitis appeared more
clinically significant, being associated with a worse
tender joint count, physician visual analogue scale
(VAS) and serum IgG level [9].
We hypothesized that SLE patients presenting with in-
flammatory joint disease would demonstrate a better
clinical response to therapy if synovitis was confirmed
by US. To test this hypothesis we conducted a pro-
spective, longitudinal, multicentre study: US Evaluation
For mUsculoskeletal Lupus (USEFUL). The primary ob-
jective was to determine whether patients with US syno-
vitis had better clinical responses to glucocorticoid
therapy compared with patients without US synovitis.
Other objectives included a comparison of US with the
clinical variables at baseline to understand which are
most useful when evaluating SLE patients.
Methods
The study was approved by the North West Greater
Manchester Central Research Ethics Committee (refer-
ence 16/NW/0060). All participants gave written consent.
Full details about the methodology can be found in the
supplementary files, available at Rheumatology online.
Patients and design
A prospective longitudinal UK multicentre cohort study
was conducted in adults with SLE (meeting the revised
ACR/SLICC 2012 criteria) [10], deemed by their physi-
cians to have inflammatory joint pain requiring gluco-
corticoid therapy (swollen joints or specific BILAG-2004/
SLEDAI-2K scores were not required). Stable doses of
immunosuppressants and prednisolone up to 5 mg were
permitted. All patients recruited received one injection of
i.m. methylprednisolone acetate 120 mg at week 0 and
had clinical and US assessments at weeks 0, 2 and 6
(Fig. 1).
Data and outcomes
Physician assessments included demographics, BILAG-
2004, SLEDAI-2K, joint counts and global and musculo-
skeletal VASs, inflammatory markers and lupus serology
and recorded features of inflammation, FM, OA, early
morning stiffness (EMS) and prior response to therapy.
Patient-reported outcomes (LupusQoL, L-QoL, EMS
min, EMS severity VAS, Likert scale for improvement in
symptoms and patient-acceptable symptom state) were
collected [11]. US was used to assess greyscale (GS),
power Doppler (PD) and tenosynovitis according to
OMERACT criteria [12, 13] in both hands and wrists. US
was deemed ‘positive’ if there was synovitis GS 2
and/or PD 1 or tenosynovitis GS 1 and/or PD 1.
Physicians, ultrasonographers and patients were all
blinded to each other’s assessments.
Details of US assessments are given in the supple-
mentary methods, available at Rheumatology online. All
sonographers attended a training event at baseline. The
same four SLE patients were scored by each sonogra-
pher and proportions of agreement were calculated.
These were GS j¼0.69, PD j¼0.98 and erosions
j¼0.85.
Internal pilot
There were limited existing data on the most appropriate
clinical measure of improvement [14]. We therefore con-
ducted an internal pilot analysis of the first 70 patients
(clinical data only). In this analysis we evaluated various
clinical variables with the best association with patient-
reported improvement in symptoms based on a Likert
scale. This determined power calculations for the full
study and how many further patients should be
recruited.
Change in the EMS severity based on VAS (EMS-VAS,
mm) at week 2 from baseline (week 0) was selected as
the primary outcome (see supplementary material, Table
S1, available at Rheumatology online). In other inflam-
matory arthritis, this scale is better at discriminating high
and low disease activity and more responsive than EMS
duration [15, 16]. We considered a difference of 20%
compared with US-inactive to be the minimum differ-
ence of interest.
Statistical analyses
At baseline, descriptive data were presented on levels of
agreement between US activity and joint swelling,
BILAG-2004 and SLEDAI-2K musculoskeletal grades. In
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order to understand which symptoms, signs and rou-
tine laboratory tests were associated with US activity
at baseline, we compared physician-reported features
using Pearson’s chi-squared for categorical variables
or t-tests for continuous variables. These variables
were also compared between SLEDAI-2K and BILAG-
2004 categories.
The primary outcome was compared between patients
with definite synovitis (US-active) and low-level/no syno-
vitis (US-inactive) at week 2 using quantile (median) re-
gression, with cluster-robust standard errors employed to
account for clustering of patients within centres. The pri-
mary analysis model adjusted for EMS-VAS at baseline;
the unadjusted difference is presented for comparison.
In a planned sensitivity analysis, concomitant immuno-
suppressant and oral glucocorticoid (both recorded yes/
no) were also added to the model. In a further planned
sensitivity analysis, the above approaches were
repeated in the per protocol set. Because there were a
substantial number of patients with FM, which may con-
found symptom responses, additional unplanned sensi-
tivity analyses were performed in patients deemed not
to have FM at baseline [17]. The same analytical
approach was then used to compare the other clinical
variables at 2 and 6 weeks according to baseline US ac-
tivity, controlling for baseline values of the outcome in
each case. Because BILAG-2004, SLEDAI-2K and
LupusQoL scores evaluate symptoms over the past
month, we analysed these endpoints at week 6 only,
using unadjusted changes from baseline between
groups. An additional sensitivity analysis compared un-
adjusted changes from baseline between groups for all
other clinical variables. This was added for comparison
because baseline-adjusted analyses can potentially be
biased when comparing non-randomized groups.
Detailed summary tables have been provided in the
supplementary material (available at Rheumatology on-
line). Requests for full data can be made via the corre-
sponding author.
Results
A total of 133 SLE patients were recruited and 121 com-
pleted all visits (see supplementary data, available at
Rheumatology online). Baseline characteristics are sum-
marized in Table 1.
FIG. 1 Study schematic
All patients followed the same treatment and assessment protocol. Clinical data shown from the first 70 patients was
used to decide the primary clinical response variable and thereby calculate statistical power. Additional patients were
then recruited to this target. US data was not unblinded until all patients were recruited.
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Association of clinical features and US synovitis
status
Active arthritis on US examination (‘active US’) was
more likely if the clinical presentation included joint
swelling, a symmetrical small joint distribution and active
serology. Physician report of EMS, a common symptom
used to identify inflammatory arthritis in routine practice,
was not associated with US findings. There was also no
association between active US findings and other SLE
features nor with the physician’s impression of their prior
response to therapy (Table 1).
We found no association between ethnicity and US
features, although low numbers of non-white, non-South
Asian patients limited this analysis. Although there were
only seven men in this study, all of them had US
synovitis.
There was substantial disagreement between US and
conventional clinical definitions of disease activity
(Table 2).
We compared swollen joint counts in all joints with US
scans in the hands and wrists (a typical US examination
in routine practice, confirmed as clinically relevant in our
previous study and systematic review [3, 9]; Table 2A).
Thirteen of 66 (20%) patients with clinical joint swelling
did not have active US. Twenty-five of 78 (32%) patients
with active US findings did not have joint swelling.
TABLE 1 Clinical characteristics and US findings at baseline
Characteristics All patients
(N 5 133)






Completed all study visits per protocol 121/133 (91) 52/55 (95) 69/78 (88) N/A
Demographics
Age, years, mean (S.D.) 46.1 (13.5) 47.9 (12.3) 44.8 (14.3) 0.190
Disease duration, years, mean (S.D.) 9.3 (8.9) 10.2 (9.8) 8.7 (8.1) 0.352
Male, n/N (%) 7/133 (5) 0/55 0 7/78 (9) 0.022
Therapy, n/N (%)
NSAID or COX-2 inhibitor 27/133 (20) 12/55 (22) 15/78 (19) 0.421
Prednisolone (maximum 5 mg/day) 31/133 (23) 12/55 (22) 19/78 (24) 0.733
Antimalarials 89/133 (67) 38/55 (69) 51/78 (65) 0.456
Immunosuppressant (MMF, MTX, AZA) 40/133 (30) 17/55 (31) 23/78 (29) 0.125
Biologic 0 (0) 0 (0) 0 (0) NA
Inflammatory features (physician rated), n/N (%)
EMS 115/133 (86) 47/55 (85) 68/78 (87) 0.775
Distribution 113/133 (85) 43/55 (78) 70/78 (90) 0.066
Symmetry 121/133 (91) 46/55 (84) 75/78 (96) 0.013
Swelling 83/132 (63) 28/54 (52) 55/78 (71) 0.029
Serology 87/130 (67) 31/53 (58) 56/77 (73) 0.090
Other lupus features 66/133 (50) 26/55 (47) 40/78 (51) 0.649
Prior therapy response 87/133 (65) 39/55 (71) 48/78 (62) 0.263
Jaccoud arthropathy 6/133 (5) 2/55 (4) 4/78 (5) 0.683
Deformity 6/133 (5) 2/55 (4) 4/78 (5) 0.683
Other lupus inflammatory 3/133 (2) 2/55 (4) 1/78 (1) 0.368
FM features, n/N (%)
Overall opinion of FM 32/133 (24) 14/55 (25) 18/78 (23) 0.752
Fatigue 30/132 (23) 12/55 (22) 18/77 (23) 0.833
Waking unrefreshed 24/132 (18) 9/55 (16) 15/77 (19) 0.647
Cognitive symptoms 20/132 (15) 7/55 (13) 13/77 (17) 0.511
Other somatic symptoms 15/132 (11) 8/55 (15) 7/77 (9) 0.330
Associated disorders (e.g. IBS) 5/133 (4) 4/55 (7) 1/78 (1) 0.074
OA features, n/N (%)
Overall opinion of OA 36/133 (27) 16/55 (29) 20/78 (26) 0.659
Hard tissue enlargement >1 joint 25/133(19) 13/54 (24) 12/77 (16) 0.224
Hard tissue enlargement DIPs 22/133(17) 11/55 (20) 11/77 (14) 0.385
Deformities consistent with OA 14/133(11) 6/55 (11) 8/77 (10) 0.924
Previous radiographic evidence 10/133(8) 3/54 (6) 7/74 (9) 0.416
Other OA features present 5/133(4) 1/54 (2) 4/78 (5) 0.332
Other musculoskeletal disorders, n/N (%)
Any other MSK disorder 9/133 (7) 4/55 5/78 N/A
All data are chi-squared tests except age and disease duration, which are t-tests.
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To evaluate the same set of joints, we evaluated clin-
ical joint swelling in the 22 joints included in the US
scan (Table 2B). This reduced the number of swollen
joints not confirmed as having active US, but clinical
examination remained insensitive.
Nineteen of 78 (24%) patients scored for arthritis on
the SLEDAI-2K did not have active US. Also, 19 of 78
(24%) patients with active US were not scored for arth-
ritis on the SLEDAI-2K.
Thirteen of 66 (20%) patients who scored A or B for
the musculoskeletal BILAG-2004 did not have active
US. Twenty-five of 78 (32%) patients with active US did
not score A or B on the musculoskeletal domain of the
BILAG-2004. BILAG-2004 includes a ‘C’ grade repre-
senting inflammatory pain. All patients in the study met
this grade since it matched the eligibility criteria.
Notably, however, the majority of patients with BILAG-
2004 C [42/67 (63%)] did not actually have active US
findings. It must be noted that BILAG-2004 and SLEDAI-
2K scores could also be influenced by joints that were
not included in the US examination. Full details of the
BILAG and SLEDAI associations are shown in
Supplementary Tables S2 and S3, available at
Rheumatology online.
Patients with active US had statistically significant
worse symptoms and signs of lupus arthritis
(Supplementary Table S4, available at Rheumatology on-
line) and higher ESR and total IgG levels (Supplementary
Table S4, available at Rheumatology online). There was
a trend towards association between active US and
anti-Sm and anti-RNP antibodies (Supplementary Table
S5, available at Rheumatology online). Twenty of 26
(77%) Sm-positive patients had active US, compared
with 58 of 107 (55%) of Sm-negative patients
(P¼0.035). Similarly, 17 of 22 (77%) RNP-positive
patients had active US compared with 61 of 111 (55%)
RNP-negative patients (P¼ 0.052).
Quality of life scores as measured by the LupusQoL
were similar in patients with active and inactive US
(Supplementary Table S6, available at Rheumatology on-
line). Exclusion of patients with FM did not change this
result (data not shown). All patients in this study had ac-
tive joint symptoms requiring increased therapy at base-
line, therefore they would be expected to rate their
quality of life as being affected even if this was not due
to active inflammation.
Primary outcome
Results from the primary outcome analysis are shown in
Fig. 2, with full statistical data in Supplementary Table
S7, available at Rheumatology online.
In the full analysis set (N¼133) the mean baseline
EMS-VAS was 57.7 mm (S.D. 4.1) in US-inactive patients
and 58.6 mm (S.D. 5.9) in US-active patients. The primary
efficacy analysis showed no clinically or statistically sig-
nificant difference between these groups [baseline-
adjusted difference 7.7 mm (95% CI 19.0, 3.5),
P¼0.178]. The planned sensitivity analysis, which was
also adjusted for immunosuppressant and oral gluco-
corticoid use, did not substantially affect this result
TABLE 2 Agreement between clinical and US assessments at baseline
(A) Clinical joint swelling (any joint) vs US synovitis (hands/wrists)
1 swollen joints, n (%) 0 swollen joints, n (%) Total, N (%)
US inactive (<GS2 and <PD1 all joints) 13 (10) 42 (32) 55 (41)
US active (GS2 or PD1 in 1 joint) 53 (40) 25 (19) 78 (59)
Total 66 (50) 67 (50) 133
(B) Clinical joint swelling (hands/wrists) vs US synovitis (hands/wrists)
1 swollen joints, n (%) 0 swollen joints, n (%) Total, N (%)
US inactive (<GS2 and <PD1 all joints) 6 (4) 49 (37) 55 (41)
US active (GS2 or PD1 in 1 joint) 54 (41) 24 (18) 78 (59)
Total 60 (45) 73 (55) 133
(C) SLEDAI-2K arthritis vs US synovitis
Arthritis, yes, n (%) Arthritis, no, n (%) Total, N (%)
US inactive (<GS2 and <PD1 all joints) 19 (14) 36 (27) 55 (41)
US active (GS2 or PD1 in 1 joint) 59 (44) 19 (14) 78 (59)
Total 78 (59) 55 (41) 133
(D) BILAG-2004 musculoskeletal domain vs US synovitis
BILAG A, n (%) BILAG B, n (%) BILAG C, n (%) Total, N (%)
US inactive (<GS2 and <PD1 all joints) 3 (2) 10 (7) 42 (32) 55 (41)
US active (GS2 or PD1 in 1 joint) 11 (8) 42 (32) 25 (19) 78 (59)
Total 14 (11) 52 (39) 67 (50) 133
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[6.3 mm (95% CI 18.1, 5.5), P¼ 0.293]. Results in the
per-protocol set (n¼122) were broadly similar.
Post hoc analyses in patients without concurrent FM
Thirty-two patients had a clinician diagnosis of FM at base-
line (which generally does not respond to glucocorticoids
[18]). In patients without FM (n¼101), the mean baseline
EMS-VAS was 56.3 mm (S.D. 4.5) in US-inactive patients
and 51.4 mm (S.D. 6.0) in US-active patients. An unplanned
sensitivity analysis, repeating the baseline-adjusted primary
analysis in this group, showed a significantly lower EMS-
VAS at 2 weeks in patients with US synovitis at baseline
[US-activeUS-inactive 12.1 (95% CI 24.1, 0.1),
P¼ 0.049]. This difference was greater in the treatment-
adjusted sensitivity analysis [12.8 (95% CI 22.2, 3.44),
P¼ 0.007] and in the per-protocol treatment-adjusted sen-
sitivity analysis [14.8 (95% CI 20.8, 8.8), P<0.001].
Other clinical endpoints
The BILAG-2004 and SLEDAI scores (which include
manifestations from the previous 30 days) at 6 weeks
according to baseline US activity are shown in Fig. 3
and Supplementary Tables S8–S9, available at
Rheumatology online. In the full analysis set (N¼ 133)
the musculoskeletal BILAG improved (reduced by at
least one grade, i.e. A to B, B to C or C to D) in 32% of
US-inactive patients and 51% of US-active patients
[odds ratio (OR) 2.15 (95% CI 1.10, 4.17), P¼ 0.024].
The SLEDAI-2K arthritis criterion improved (resolution of
arthritis criterion) in 22% of US-inactive patients and
38% of US-active patients [OR 2.17 (95% CI 1.41, 3.35),
P<0.001].
The improved responses in US-active patients were
again more evident in patients without FM (n¼101). The
musculoskeletal BILAG-2004 improved in 26% of US-
inactive patients and 56% of US-active patients [OR
FIG. 2 Primary endpoint: clinical response according to baseline US
(A) Primary efficacy variable (EMS-VAS at week 2) according to baseline US status. Vertical dotted line indicates de-
gree of improvement in patients with active US at baseline was the same as patients with inactive US at baseline.
Values to the left of this line show patients with active US at baseline had better response to therapy. Primary ana-
lysis model was adjusted for the baseline EMS-VAS only. Sensitivity analysis was also adjusted for use of NSAIDs,
prednisolone and immunosuppressants. Analyses were also repeated for per-protocol population and exclusion of
patients with FM. (B–E) Improvement in musculoskeletal components of the BILAG and SLEDAI according to baseline
US status. (B) Percentage of patients with improvement in the musculoskeletal component of the BILAG.
Improvement was defined as a reduction by at least one grade (i.e. A to B, B to C or C to D). (C) Same analyses
excluding patients with FM. (D) Percentage of patients with improvement in the musculoskeletal items on the SLEDAI
(arthritis and myositis, although no patient in this study was scored for myositis). Improvement was therefore defined
as resolution of arthritis (reduction from 4 points to 0 points). (E) Same analysis excluding patients with FM.
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3.74 (95% CI 2.03, 6.90), P<0.001]. The musculoskel-
etal SLEDAI-2K improved in 15% of US-inactive patients
and 37% of US-active patients [OR 3.24 (95% CI 1.62,
6.50), P¼ 0.001].
Data for other clinical outcomes at 2 and 6 weeks are
shown in Supplementary Tables S10 and S11, available
at Rheumatology online.
Quality of life
Three domains of the LupusQoL also showed greater
improvement in US-active patients (Table 3).
Significantly greater improvement was seen in US-active
patients for the physical health, burden to others and
body image domains. The size of these effects differed
slightly between the 2 and 6 week time points and be-
tween the primary and sensitivity analysis. The three
domains that appear most relevant to musculoskeletal
symptoms are shown in Fig. 3. Although the direction of
the numerical differences favoured US-active patients in
all cases, improvement in pain was not significantly
greater for US-active patients. Patients without FM were
significantly more likely to achieve a patient-acceptable
symptom state at week 2 if US was active at baseline
[38% vs 32%; baseline-adjusted primary OR 1.75 (95%
CI 1.22, 2.49), P¼0.002].
Sensitivity analyses for secondary clinical endpoints
Sensitivity analyses comparing unadjusted changes from
baseline between groups (Supplementary Tables S8 and
9 and S12 and 13, available at Rheumatology online)
generally indicated the same direction of effect for pri-
mary and secondary outcomes compared with the main
analysis. When patients with FM were excluded, both
analysis methods agreed the response was greater in
those with baseline US-active for EMS-VAS and the
LupusQoL domain ‘burden to others’ as well as the
FIG. 3 Change in the three most relevant domains of LupusQoL according to baseline US status
The vertical dotted line indicates that the degree of improvement in patients with active US at baseline was the same
as for patients with inactive US at baseline. Values to the left of this line indicate a better response in patients with
active US at baseline. The primary analysis model was adjusted for baseline values. The sensitivity analysis was also
adjusted for use of NSAIDs, prednisolone and immunosuppressants. These analyses were repeated excluding
patients with FM.
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musculoskeletal SLEDAI at week 6. However, for phys-
ician global and musculoskeletal VAS, the two analysis
methods disagreed over the direction of effect.
Discussion
This study reports the most comprehensive clinical and
US data to define which SLE patients with inflammatory
joint symptoms are most responsive to glucocorticoid
therapy. We demonstrated disagreement between US
synovitis and features commonly used to guide immuno-
suppressive therapy: joint swelling or completion of the
BILAG-2004 and SLEDAI-2K indices. Although the pri-
mary outcome was not met, this may be due to a large
proportion of patients having FM. When they were
excluded, we found a greater clinical response to gluco-
corticoids in participants with US synovitis at baseline in
several clinical and patient-reported endpoints. These
results have importance for the selection of patients for
therapy in routine practice, clinical trials in SLE and the
utility of US in this disease.
Despite the availability of licensed immunosuppressive
therapies, musculoskeletal symptoms continue to have
a major negative impact on quality of life in patients with
SLE [1]. Our results suggest that patients with no swel-
ling but positive US synovitis may benefit from escalat-
ing immunosuppressive therapy. Conversely, a negative
US may indicate that it is safe to continue to taper glu-
cocorticoids, which is important given the toxicity of
long-term glucocorticoids.
If US is not available, the most useful signs indicating
active joint inflammation are distribution, swelling and
symmetry. Some other symptoms (EMS, other lupus
features, prior therapy response) commonly used in
practice may not be helpful. Consistent with our previ-
ous work, the level of IgG may be useful in identifying
active lupus arthritis [9]. Sm and RNP antibodies are
also helpful.
Despite the negative impact of FM on responsiveness,
it is important to note that we confirmed US-proven in-
flammation in patients who also had this condition.
There may be longer-term benefits of treatment in these
patients. The number of patients diagnosed with FM in
our study was high compared with unselected SLE
cohorts [19], which is not surprising since the main in-
clusion criterion was pain.
Accurate scoring of US using OMERACT criteria was
an important feature of this study. We previously high-
lighted the need for standardization of US-reporting in
SLE studies in our systematic literature review [3]. We
then validated the OMERACT scoring in SLE in two
other studies. In a cross-sectional study we showed that
OMERACT-scored US had face validity and concurrent
validity (association with BILAG-2004 and SLEDAI
scores) [8, 20, 21]. In a longitudinal study we showed
that OMERACT-scored synovitis was responsive after
120 mg methylprednisolone acetate [14]. The data from
the present study fulfil another criterion in the
OMERACT filter for validation of US as an outcome
measure in SLE [22]. For the first time we demonstrate
that it has OMERACT-scored US has predictive validity
for therapy response.
Many clinical trials of new therapies in SLE failed to
demonstrate any benefit even though there were rea-
sons to believe these therapies should have been effect-
ive [23–32]. Our results help to define a target
population to enrol or enrich clinical trials with confirmed
synovitis and consequent greater response to therapy.
Usually eligibility is based on clinical examination for
swollen joints. We showed that 20% of such patients do
not have active synovitis. Further, we showed that al-
though patients with FM may have confirmed active
synovitis, this comorbidity confounds assessment of re-
sponse. Hence our results suggest that the use of US
(or other imaging) synovitis as an inclusion criterion and
exclusion of patients with significant FM that would af-
fect disease activity assessment may result in larger ef-
fect sizes in clinical trials of new therapies.
The main limitation of our study is the open-label de-
sign; this limits understanding of how these patient se-
lection criteria would function in a randomized controlled
trial (RCT). Although US is a more sensitive test of in-
flammation than clinical examination, there could be
immune-mediated causes of pain that are not well cap-
tured by this tool, such as bone oedema [33]. The FM
analysis was post hoc. However, it is logical, in line with
clinical practice, since FM is a well-known comorbidity
that influences response to therapy [34]. Since our study
began, the presence and potential significance of enthe-
sitis has been reported in SLE patients [35]. We did not
assess this because we based our US reporting on a
systematic review of the published literature at the time.
Lastly, a possible explanation for the discrepancy be-
tween US and BILAG-2004 and SLEDAI scores was that
US was only done on hands while the BILAG and
SLEDAI take into account all joints. The data in Table 2
provide an indication of this effect. In our previous study
we analysed agreement between US and clinical exam-
ination and found this was greatest in the small joints of
the hand. It is therefore possible that the BILAG and
SLEDAI could be modified in the future to include the
clinical features that are best validated by US. For ex-
ample, the definition of synovitis for BILAG A or B could
specify joints in the hands and wrists and the definition
of arthralgia for BILAG C could specify a symmetrical
small joint distribution. BILAG-2004 and SLEDAI are also
dependent on the training of the assessor. Our study
was conducted in BILAG member centres. In a less-
specialist setting, these instruments may have per-
formed worse compared with US.
Future research should evaluate the use of US in
randomized trials to determine whether it can measure
and stratify differences between treatment groups. Such
an RCT is in progress [Rituximab Objective Outcome
Measures Trial in SLE (NCT03054259)]. Future work will
define clinical outcome measures for musculoskeletal
disease activity that better match the results obtained
from US.
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In conclusion, our data suggest that US synovitis is
clinically important and responsive to therapy in SLE.
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